Paclitaxel and gemcitabine in advanced non-nasopharyngeal head and neck cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group

Annals of Oncology

Volumn 10, Issue 4, 1999, Pages 475-478

  Fountzilas, George ^a   Stathopoulos, G ^b   Nicolaides, C ^c   Kalogera Fountzila, A ^a   Kalofonos, H ^d   Nikolaou, A ^a   Bacoyiannis, C ^e   Samantas, E ^f   Papadimitriou, C ^g   Kosmidis, P ^e   Daniilidis, J ^a   Pavlidis, N ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Ippokration Hospital Thessaloniki   (Greece)

^c UNIVERSITY OF IOANNINA   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e METAXA CANCER HOSPITAL   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g ALEXANDRA HOSPITAL   (Greece)

Author keywords

Chemotherapy; Gemcitabine; Head and neck tumors; Paclitaxel

Indexed keywords

GEMCITABINE; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER LOCALIZATION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; FLU LIKE SYNDROME; HEAD AND NECK CARCINOMA; HUMAN; LARYNX CARCINOMA; MALE; MOUTH CARCINOMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; GREECE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PACLITAXEL; PROGNOSIS; SURVIVAL RATE;

EID: 0032960189     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008397424359     Document Type: Article

References (12)

1. Vokes EE, Athanasiadis I. Chemotherapy for squamous cell carcinoma of head and neck: The future is now. Ann Oncol 1996; 7: 15-29.
2. Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma or the head and neck. J Clin Oncol 1992; 10: 257-63.
3. Forastiere AA, Shank D, Neuberg D et al. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: An Eastern Cooperative Oncology Group Trial (PA 390). Cancer 1998; 82: 2270-4.
4. Catimel G, Verweij J, Mattijssen V et al. Docetaxel (Taxotere): An active drug of the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
5. Catimel G, Vermorken JB, Clavel M et al. A phase II study of gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
6. Theodossiou C, Cook JA, Fisher J et al. Interaction of gemcitabine with paclitaxel and cisplatin in human tumor cell lines. Int J Oncol 1998; 12: 825-32.
7. Jensen PB, Holm B, Sorensen M. In vitro cross resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines. Preclinical identification of suitable drug partners to Taxotere, topotecan and gemcitabine. Br J Cancer 1997; 75: 869-77.
8. Fountzilas G, Papadimitriou V, Bafaloukos D et al. Paclitaxel and carboplatin as first-line chemotherapy for advanced breast cancer. Oncology 1998; 12(Suppl 1): 45-8.
9. Poole CJ, Perren T, Hogberg T et al. Phase I study to investigate alternate sequencing of the combination of gemcitabine and paclitaxel in ovarian carcinoma. Eur J Cancer 1997; 33 (Suppl 8): S121 (Abstr).
10. Fountzilas G, Skarlos D, Athanassiadis A et al. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study. Ann Oncol 1997; 8: 451-5.
11. Dombernowsky P, Giaccone G, Sandler A et al. Gemcitabine and paclitaxel combinations in non-small-cell lung cancer. Semin Oncol 1998; 25: 44-50.
12. Androulakis N, Kouroussis C, Kakolyris S et al. Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin-or docetaxel-based chemotherapy: A multicenter phase II study. 1998; 9: 1127-30.